Skip to main
CATX

CATX Stock Forecast & Price Target

CATX Analyst Ratings

Based on 8 analyst ratings
Strong Buy
Strong Buy 63%
Buy 38%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Perspective Therapeutics Inc. is positioned favorably within the radiopharmaceutical market, particularly with its lead program VMT-α-NET, which shows potential in targeting a multi-billion-dollar market in neuroendocrine tumors (NET). The company leverages the alpha-emitting isotope Lead-212 (212Pb), which is recognized for its superior safety and efficacy profile compared to other developing radioisotopes, providing a distinct advantage in cancer treatment. Furthermore, promising clinical data indicates that VMT-α-NET has significantly improved response rates and durability over current standard treatments, suggesting a robust pipeline that could attract ongoing investment and bolster the stock's performance as additional data becomes available.

Bears say

The analysis of Perspective Therapeutics Inc reveals several key factors contributing to a negative outlook on the stock. Firstly, despite a significant unmet need for treatments in advanced cancer stages, the company faces intense competition and commercialization risks, particularly as it may struggle to offer pricing competitive enough to gain adequate reimbursement. Additionally, challenges in meeting demand and quality control issues experienced by competitors, such as Novartis, may indicate systemic vulnerabilities within the radiopharmaceutical industry's supply chain that could affect Perspective's market position.

CATX has been analyzed by 8 analysts, with a consensus rating of Strong Buy. 63% of analysts recommend a Strong Buy, 38% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Perspective Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Perspective Therapeutics Inc (CATX) Forecast

Analysts have given CATX a Strong Buy based on their latest research and market trends.

According to 8 analysts, CATX has a Strong Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Perspective Therapeutics Inc (CATX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.